1037P Taxol-ramucirumab-pembrolizumab (TRP) for immuno-resistant/refractory NSCLC
| Autor: | Niu, J.J., Amado, A., Zhou, J., Hebert, M., Liu-Dumlao, T., Capozzi, M., Lindebak, S.E. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1029-S1029 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|